共 303 条
[21]
Flexner C(2001)Impact of nelfinavir resistance mutations on AIDS Res Hum Retroviruses 17 211-5
[22]
Pellegrin I(1999) phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases AIDS 13 F23-8
[23]
Breilh D(2004)R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen AIDS 18 651-5
[24]
Montestruc F(2001)Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene Antivir Ther 6 185-9
[25]
Kemper CA(1998)Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir AIDS 12 F111-5
[26]
Witt MD(2004)GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks HIV Med 5 307-13
[27]
Keiser PH(2005)Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir AIDS 19 371-80
[28]
Hirsch MS(1998)The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy J Clin Invest 101 2394-405
[29]
Brun-Vézinet F(2000)Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients AIDS Res Hum Retroviruses 16 559-67
[30]
D’Aquila RT(1999)An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologie response in HIV-1 infected children Cell Death Differ 6 420-32